Open Access Open Access  Restricted Access Subscription Access

Drugs Used in the Treatment of Skin Disorders

Muralinath E., Pooja Devi, Prasanta Chbukdhara, Sanjib Borah, Kalyan C., Archana Jain, Guruprasad M.

Abstract


The human skin is the body’s largest organ. A wide range of drugs are present to treat the skin disorders. Topical corticosteroids are widely used for Treating dermatitis, eczema and psoriasis. Topical corticosteroids are specifically used for short periods such as a few days to a few weeks. Prolonged use of Topical corticosteroids caused side effects namely skin discoloration, skin thinning and development of stretch marks. Fungal skin infections namely athletes foot, fungal nail infection and ring worm can bectreated in an effective manner. Antifungal medications are available in both Topical and oral forms. Some common antifungal medications are clotrimazole, fluconazole, ketoconazole, miconazole, terbinafine. Antifungals are helpful in treating various types of fungal infections simuch as athletes foot, jock inch, ring worm and yeast infections, Antibiotics are helpful in treating bacterial skin infections namely cellulitis, folliculitis and impetigo. Topical antibiotics namely mupirocin or neomycin is helpful in treating localized skin infections. Oral Antibiotics namely amixycillin, cephalexin and penicillin are useful for treating severe or widespread infections. Allergic reactions, diarrhea, and upset stomach are among the relatively few common adverse reactions of antibiotics. Retinoids are made of vitamin A, are also helpful in treating a very few skin disorders include acne and psoriasis. Retinoids are also useful for treating their anti-aging properties. Tazarotene is also useful to treat psoriasis. Drugs namely pimecrolimus (Elide) and tacrolimus (Protopic) are also helpful in treating eczema. It is finally concluded that there are a variety of drugs to treat the skin infections.


Full Text:

PDF

References


Novartis, P. (2018, September). Targeted therapies for psoriatic arthritis: an update for the dermatologist. In Seminars in cutaneous medicine and surgery (Vol. 37, pp. 173-181).

Yiu, Z. Z., & Warren, R. B. (2018, September). Ustekinumab for the treatment of psoriasis: an evidence update. In Seminars in Cutaneous Medicine and Surgery (Vol. 37, No. 3, pp. 143-147).

Yang, E. J., Beck, K. M., Sanchez, I. M., Koo, J., & Liao, W. (2018). The impact of genital psoriasis on quality of life: a systematic review. Psoriasis: Targets and Therapy, 41-47.

Gamret, A. C., Price, A., Fertig, R. M., Lev-Tov, H., & Nichols, A. J. (2018). Complementary and alternative medicine therapies for psoriasis: a systematic review. JAMA dermatology, 154(11), 1330-1337.

Nguyen, C. T., Bloch, Y., Składanowska, K., Savvides, S. N., & Adamopoulos, I. E. (2019). Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight. Clinical immunology, 206, 15-22.

Larsabal, M., Ly, S., Sbidian, E., Moyal‐Barracco, M., Dauendorffer, J. N., Dupin, N., ... & Villani, A. (2019). GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. British Journal of Dermatology, 180(3), 647-656.

Eder, L., Widdifield, J., Rosen, C. F., Cook, R., Lee, K. A., Alhusayen, R., ... & Tu, K. (2019). Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: a population‐based study. Arthritis care & research, 71(8), 1084-1091.

Kahn, J., Deverapalli, S. C., & Rosmarin, D. (2018, September). JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases. In Seminars in Cutaneous Medicine and Surgery (Vol. 37, No. 3, pp. 198-208).

Caiazzo, G., Fabbrocini, G., Di Caprio, R., Raimondo, A., Scala, E., Balato, N., & Balato, A. (2018). Psoriasis, cardiovascular events, and biologics: lights and shadows. Frontiers in immunology, 9, 1668.

Trayes, K. P., Savage, K., & Studdiford, J. S. (2018). Annular lesions: diagnosis and treatment. American Family Physician, 98(5), 283-291.

Vázquez-Herrera, N. E., Sharma, D., Aleid, N. M., & Tosti, A. (2018). Scalp itch: a systematic review. Skin appendage disorders, 4(3), 187-199.

Perez-Chada, L. M., Cohen, J. M., Gottlieb, A. B., Duffin, K. C., Garg, A., Latella, J., ... & Merola, J. F. (2018). Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative. Archives of Dermatological Research, 310, 701-710.

Schadler, E. D., Ortel, B., & Mehlis, S. L. (2019). Biologics for the primary care physician: Review and treatment of psoriasis. Disease-a-Month, 65(3), 51-90.

Dauden, E., Blasco, A. J., Bonanad, C., Botella, R., Carrascosa, J. M., González‐Parra, E., ... & Rivera, R. (2018). Position statement for the management of comorbidities in psoriasis. Journal of the European Academy of Dermatology and Venereology, 32(12), 2058-2073.

Luchetti, M. M., Benfaremo, D., Campanati, A., Molinelli, E., Ciferri, M., Cataldi, S., ... & Gabrielli, A. (2018). Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic. Clinical Rheumatology, 37, 2741-2749.


Refbacks

  • There are currently no refbacks.